Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Mycobacterium tuberculosis Protein Ag85A Products under Development by Stage of Development | 7 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Products under Development by Therapy Area | 8 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Products under Development by Indication | 9 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Products under Development by Companies | 11 | 2 |
| Mycobacterium tuberculosis Protein Ag85A Products under Development by Universities/Institutes | 13 | 2 |
| Mycobacterium tuberculosis Protein Ag85A Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Mycobacterium tuberculosis Protein Ag85A Companies Involved in Therapeutics Development | 20 | 1 |
| Imaxio SA | 20 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Drug Profiles | 21 | 14 |
| HG-85A Drug Profile | 21 | 1 |
| HG-85A/B Drug Profile | 22 | 1 |
| HG856-A Drug Profile | 23 | 1 |
| HG856-BCG Drug Profile | 24 | 1 |
| HG856-SeV Drug Profile | 25 | 1 |
| IMX-313-TB Drug Profile | 26 | 1 |
| MVA-85A Drug Profile | 27 | 4 |
| TB/FLU-04L Drug Profile | 31 | 1 |
| tuberculosis vaccine Drug Profile | 32 | 1 |
| tuberculosis vaccine Drug Profile | 33 | 1 |
| tuberculosis vaccine 2 Drug Profile | 34 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Dormant Projects | 35 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Discontinued Products | 36 | 1 |
| Mycobacterium tuberculosis Protein Ag85A Featured News &Press Releases | 37 | 10 |
| Mar 24, 2015: World-first TB vaccination trials enter next stage | 37 | 1 |
| Oct 02, 2013: New tuberculosis vaccine will help fight 'serious public health threat' | 38 | 1 |
| Sep 03, 2013: Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis | 39 | 1 |
| Feb 04, 2013: Emergent BioSolutions Reports Publication Of Data From Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A In Lancet | 39 | 2 |
| Dec 10, 2012: University Of Cape Town Begins New study On TB Vaccine For Newborns Of HIV-positive Mothers | 41 | 1 |
| Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate | 41 | 1 |
| Aug 11, 2011: Aeras And Oxford-Emergent Tuberculosis Consortium Announce Start Of Phase IIb Trial Of New Investigational Tuberculosis Vaccine In Senegal And South Africa | 42 | 1 |
| Apr 28, 2011: Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant In Phase IIb Clinical Trial | 43 | 1 |
| Feb 25, 2011: Delegates From European Parliament Express Support For Rapid Development Of Emergent's New TB Vaccine | 44 | 1 |
| Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa | 44 | 1 |
| Jun 23, 2008: Emergent BioSolutions And University of Oxford Form Joint Venture To Develop Advanced Tuberculosis Vaccine | 45 | 1 |
| Oct 25, 2004: TB Vaccine MVA85A Succeeds In Safety Trials | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |